451 related articles for article (PubMed ID: 26210691)
1. Programmed cell death protein 1 expression is an independent prognostic factor in gastric cancer after curative resection.
Eto S; Yoshikawa K; Nishi M; Higashijima J; Tokunaga T; Nakao T; Kashihara H; Takasu C; Iwata T; Shimada M
Gastric Cancer; 2016 Apr; 19(2):466-471. PubMed ID: 26210691
[TBL] [Abstract][Full Text] [Related]
2. Programmed Cell Death Ligand 1 Expression Is an Independent Prognostic Factor in Colorectal Cancer.
Enkhbat T; Nishi M; Takasu C; Yoshikawa K; Jun H; Tokunaga T; Kashihara H; Ishikawa D; Shimada M
Anticancer Res; 2018 Jun; 38(6):3367-3373. PubMed ID: 29848685
[TBL] [Abstract][Full Text] [Related]
3. Impact of sidedness of colorectal cancer on tumor immunity.
Takasu C; Nishi M; Yoshikawa K; Tokunaga T; Kashihara H; Yoshimoto T; Shimada M
PLoS One; 2020; 15(10):e0240408. PubMed ID: 33045001
[TBL] [Abstract][Full Text] [Related]
4. Prognostic impacts of the combined positive score and the tumor proportion score for programmed death ligand-1 expression by double immunohistochemical staining in patients with advanced gastric cancer.
Yamashita K; Iwatsuki M; Harada K; Eto K; Hiyoshi Y; Ishimoto T; Nagai Y; Iwagami S; Miyamoto Y; Yoshida N; Komohara Y; Ajani JA; Baba H
Gastric Cancer; 2020 Jan; 23(1):95-104. PubMed ID: 31451991
[TBL] [Abstract][Full Text] [Related]
5. Programmed cell death ligand 1 (PD-L1) expression on gastric cancer and its relationship with clinicopathologic factors.
Zhang L; Qiu M; Jin Y; Ji J; Li B; Wang X; Yan S; Xu R; Yang D
Int J Clin Exp Pathol; 2015; 8(9):11084-91. PubMed ID: 26617827
[TBL] [Abstract][Full Text] [Related]
6. Clinical significance of programmed death 1/programmed death ligand 1 pathway in gastric neuroendocrine carcinomas.
Yang MW; Fu XL; Jiang YS; Chen XJ; Tao LY; Yang JY; Huo YM; Liu W; Zhang JF; Liu PF; Liu Q; Hua R; Zhang ZG; Sun YW; Liu DJ
World J Gastroenterol; 2019 Apr; 25(14):1684-1696. PubMed ID: 31011254
[TBL] [Abstract][Full Text] [Related]
7. Immunochemotherapy benefits in gastric cancer patients stratified by programmed death-1 ligand-1.
Hsu JT; Hsu CS; Le PH; Chen TC; Chou WC; Lin CY; Yeh TS
J Surg Res; 2017 May; 211():30-38. PubMed ID: 28501128
[TBL] [Abstract][Full Text] [Related]
8. MiR-21 Participates in the PD-1/PD-L1 Pathway-Mediated Imbalance of Th17/Treg Cells in Patients After Gastric Cancer Resection.
Zheng X; Dong L; Wang K; Zou H; Zhao S; Wang Y; Wang G
Ann Surg Oncol; 2019 Mar; 26(3):884-893. PubMed ID: 30565043
[TBL] [Abstract][Full Text] [Related]
9. Prognostic significance of programmed death-1 and programmed death-ligand 1 expression in patients with esophageal squamous cell carcinoma.
Chen K; Cheng G; Zhang F; Zhang N; Li D; Jin J; Wu J; Ying L; Mao W; Su D
Oncotarget; 2016 May; 7(21):30772-80. PubMed ID: 27120796
[TBL] [Abstract][Full Text] [Related]
10. Highly Activated PD-1/PD-L1 Pathway in Gastric Cancer with PD-L1 Expression.
Saito H; Kono Y; Murakami Y; Shishido Y; Kuroda H; Matsunaga T; Fukumoto Y; Osaki T; Ashida K; Fujiwara Y
Anticancer Res; 2018 Jan; 38(1):107-112. PubMed ID: 29277762
[TBL] [Abstract][Full Text] [Related]
11. Measurement of soluble PD-1 and soluble PD-L1 as well as PD-L1 and PD-1 from perioperative patients with gastric carcinoma.
Wei H; Wu F; Mao Y; Zhang Y; Leng G; Wang J; Zhang W; Wang T
Jpn J Clin Oncol; 2022 Apr; 52(4):331-345. PubMed ID: 35106596
[TBL] [Abstract][Full Text] [Related]
12. High ratio of programmed cell death protein 1 (PD-1)(+)/CD8(+) tumor-infiltrating lymphocytes identifies a poor prognostic subset of extrahepatic bile duct cancer undergoing surgery plus adjuvant chemoradiotherapy.
Lim YJ; Koh J; Kim K; Chie EK; Kim B; Lee KB; Jang JY; Kim SW; Oh DY; Bang YJ; Ha SW
Radiother Oncol; 2015 Oct; 117(1):165-70. PubMed ID: 26235847
[TBL] [Abstract][Full Text] [Related]
13. Prognostic value of programmed death-1, programmed death-ligand 1, programmed death-ligand 2 expression, and CD8(+) T cell density in primary tumors and metastatic lymph nodes from patients with stage T1-4N+M0 gastric adenocarcinoma.
Gao Y; Li S; Xu D; Chen S; Cai Y; Jiang W; Zhang X; Sun J; Wang K; Chang B; Wang F; Hong M
Chin J Cancer; 2017 Jul; 36(1):61. PubMed ID: 28754154
[TBL] [Abstract][Full Text] [Related]
14. The Impact of Indoleamine 2,3-dioxygenase (IDO) Expression on Stage III Gastric Cancer.
Nishi M; Yoshikawa K; Higashijima J; Tokunaga T; Kashihara H; Takasu C; Ishikawa D; Wada Y; Shimada M
Anticancer Res; 2018 Jun; 38(6):3387-3392. PubMed ID: 29848687
[TBL] [Abstract][Full Text] [Related]
15. Polymorphism of the programmed death-ligand 1 gene is associated with its protein expression and prognosis in gastric cancer.
Wu Y; Zhao T; Jia Z; Cao D; Cao X; Pan Y; Zhao D; Zhang B; Jiang J
J Gastroenterol Hepatol; 2019 Jul; 34(7):1201-1207. PubMed ID: 30353572
[TBL] [Abstract][Full Text] [Related]
16. Soluble PD-L1 Expression in Circulation as a Predictive Marker for Recurrence and Prognosis in Gastric Cancer: Direct Comparison of the Clinical Burden Between Tissue and Serum PD-L1 Expression.
Shigemori T; Toiyama Y; Okugawa Y; Yamamoto A; Yin C; Narumi A; Ichikawa T; Ide S; Shimura T; Fujikawa H; Yasuda H; Hiro J; Yoshiyama S; Ohi M; Araki T; Kusunoki M
Ann Surg Oncol; 2019 Mar; 26(3):876-883. PubMed ID: 30565045
[TBL] [Abstract][Full Text] [Related]
17. Immunohistochemistry Biomarkers Predict Survival in Stage II/III Gastric Cancer Patients: From a Prospective Clinical Trial.
Kim MH; Zhang X; Jung M; Jung I; Park HS; Beom SH; Kim HS; Rha SY; Kim H; Choi YY; Son T; Kim HI; Cheong JH; Hyung WJ; Noh SH; Chung HC
Cancer Res Treat; 2019 Apr; 51(2):819-831. PubMed ID: 30282452
[TBL] [Abstract][Full Text] [Related]
18. Poor prognosis in Epstein-Barr virus-negative gastric cancer with lymphoid stroma is associated with immune phenotype.
Cho CJ; Kang HJ; Ryu YM; Park YS; Jeong HJ; Park YM; Lim H; Lee JH; Song HJ; Jung HY; Kim SY; Myung SJ
Gastric Cancer; 2018 Nov; 21(6):925-935. PubMed ID: 29627937
[TBL] [Abstract][Full Text] [Related]
19. Programmed death-ligand 1 expression in gastric adenocarcinoma is a poor prognostic factor in a high CD8+ tumor infiltrating lymphocytes group.
Chang H; Jung WY; Kang Y; Lee H; Kim A; Kim HK; Shin BK; Kim BH
Oncotarget; 2016 Dec; 7(49):80426-80434. PubMed ID: 27741514
[TBL] [Abstract][Full Text] [Related]
20. PD-L1 Expression Is a Favorable Prognostic Marker in Gastric Carcinoma.
Sughayer MA; Dabbagh TZ; Battah AH
Appl Immunohistochem Mol Morphol; 2020; 28(10):748-754. PubMed ID: 32205740
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
